Claims for Patent: 9,669,068

Summary for Patent: 9,669,068

Title:	Methods for the treatment of cancer using gliadin peptides
Abstract:	Kits and methods for treating cancer comprising administration of a gliadin peptide to a patient are disclosed herein. A kit according to the invention comprises a pharmaceutical composition comprising a gliadin peptide and instructions for administering the peptide to a patient. The kit may further comprise a pharmaceutical composition comprising at least one chemotherapeutic agent such as a receptor tyrosine kinase inhibitor and instructions for co-administering the compounds. A method of treating cancer according to the invention comprises administering a gliadin peptide to a patient and may further comprise co-administering at least one chemotherapeutic agent such as a receptor tyrosine kinase inhibitor. Co-administration of a gliadin peptide and receptor tyrosine kinase inhibitor to a patient with cancer is effective to decrease or prevent resistance of the cancer to the receptor tyrosine kinase inhibitor.
Inventor(s):	Shaw; Fred L. (Inverness, IL)
Assignee:	BARMARSA RESEARCH LLC (Inverness, IL)
Application Number:	15/007,157
Patent Claims:	1. A method of treating cancer comprising administering a therapeutically effective amount of a gliadin peptide to a patient with cancer, wherein the gliadin peptide comprises the amino acid sequence set forth in SEQ ID NO:1 and wherein the cancer is selected from the group consisting of non-small cell lung cancer and pancreatic cancer. 2. The method of claim 1, further comprising co-administering a therapeutically effective amount of at least one chemotherapeutic agent. 3. The method of claim 2, wherein the at least one chemotherapeutic agent is a receptor tyrosine kinase inhibitor. 4. The method of claim 1, wherein the gliadin peptide is an alpha-gliadin peptide selected from the group consisting of alpha-gliadin peptide p31-55, p31-49, and derivatives and fragments thereof. 5. The method of claim 1, wherein the receptor tyrosine kinase inhibitor is an epidermal growth factor receptor (EGFR) inhibitor. 6. The method of claim 5, wherein the EGFR inhibitor is gefitinib. 7. The method of claim 5, wherein the EGFR inhibitor is erlotinib. 8. The method of claim 3, wherein co-administering the gliadin peptide and receptor tyrosine kinase inhibitor is effective to decrease or prevent resistance of the cancer to the receptor tyrosine kinase inhibitor. 9. The method of claim 1, wherein the patient is human. 10. The method of claim 5, wherein the patient does not have mutations in the EGFR gene known to increase sensitivity to EGFR inhibitors. 11. The method of claim 2, wherein co-administering the gliadin peptide and at least one chemotherapeutic agent is effective to decrease or prevent resistance of the cancer to the chemotherapeutic agent. 12. The method of claim 2, wherein co-administering the gliadin peptide and at least one chemotherapeutic agent is effective to increase the efficacy of the chemotherapeutic agent. 13. The method of claim 11, wherein the chemotherapeutic agent is administered first. 14. The method of claim 2, wherein the chemotherapeutic agent is selected from the group consisting of azacitidine, axathioprine, bevacizumab, bleomycin, capecitabine, carboplatin, chlorabucil, cisplatin, cyclophosphamide, cytarabine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, etoposide, fluorouracil, gemcitabine, trastuzumab, idarubicin, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, tafluposide, teniposide, tioguanine, retinoic acid, valrubicin, vinblastine, vincristine, vindesine, vinorelbine, afatinib, axitinib, canertinib, cediranib, erlotinib, gefitinib, grandinin, imatinib, lapatinib, leflunomide, lestaurtinib, neratinib, pazopanib, quizartinib, regorafenib, semaxanib, sorafenib, sunitib, sunitinib, tivozanib, tocerabib, vandetanib, vatalanib, and combinations thereof. 15. The method of claim 1, comprising administering the gliadin peptide via a route selected from the group consisting of oral, intramuscular, intravenous, respiratory/inhalation, and subcutaneous.

Details for Patent 9,669,068

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-03-07
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2033-03-07
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2033-03-07
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2033-03-07